Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine.

BACKGROUND

The interindividual genetic variations in drug metabolizing enzymes effects the impact and toxicity in plenty of drugs.

OBJECTIVE

CYP1A2, CYP2C9, CYP2C19 and CYP2D6 gene polymorphisms were characterized using high resolution melting analysis (HRMA) in follow-up patients in psychiatry clinic as a preliminary preparation for personalized medicine.

METHOD

Genotyping of CYP1A2*1F, CYP2C9 *2, *3, CYP2C19 *2, *3 and *17 and CYP2D6 *3, *4 was conducted in 101 patients using HRMA. Genotype and allele frequencies of the CYP variants were found to be in equilibrium with the Hardy-Weinberg equation.

RESULTS

The frequency of the CYP1A21F allele in schizophrenia and bipolar disease was 0.694 and 0.255, respectively. The CYP2C9 allele frequencies were 0.087 (CYP2C92), and 0.549 (CYP2C93) for bipolar; 0.278 (CYP2C92) and 0.648 (CYP2C93) in schizophrenias. The CYP2C192 and *17 allele frequencies was 0.111 and 0.185 in schizophrenia and variant 2 was 0.117 and variant 17 was 0.255 in bipolar group. The frequency of the CYP2D63 allele was 0.027 in schizophrenias. The frequencies for the CYP2D64 variant were 0.092 and 0.096 in schizophrenia and bipolar groups, respectively.

CONCLUSION

The knowledge in pharmacogenomic and also the developments in molecular genetics are growing rapidly. In future, this can be expected to provide new methodologies in the prediction of the activity in drug metabolizing enzymes. The HRMA is a rapid and useful technique to identify the genotypes for drug dosage adjustment before therapy in psychiatry patients.